相关临床试验
10
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
30.0%
已完成
5
50.0%
招募中
1
10.0%
撤回
1
10.0%
暂无批准数据
- A Nagoya University and Fujifilm team developed "Cap-cirRNA," a circular mRNA with a cap structure combining high translation efficiency with long-term stability. - The delivery system uses Fujifilm's ionizable lipid FL0445, achieving more than 10 times the intracellular transport efficiency of conventional lipid nanoparticles. - In obese mice, circular mRNA encoding GLP-1 produced prolonged protein expression, improved blood glucose control, and suppressed the inflammatory response. - The platform shows potential for cancer vaccines, genome editing, and replacement therapy for hereditary diseases, though clinical application remains distant.
- The global bone densitometers market is projected to grow from USD 391.3 million in 2026 to USD 584.8 million by 2036 at a 4.1% CAGR, according to FMI Research. - DXA systems remain the clinical gold standard, accounting for 63.0% of total market demand in 2026, while hospitals dominate end-user share at 56.0%. - Growth is increasingly driven by value-based healthcare adoption, preventive osteoporosis screening, and hospital modernization initiatives rather than new installation volume alone. - Procurement strategies are shifting toward enterprise imaging integration, with hospitals prioritizing interoperability, cybersecurity, predictive maintenance, and long-term lifecycle value over hardware specifications.
- FUJIFILM Cellular Dynamics opened a new 175,000-square-foot headquarters and iPSC manufacturing facility in Madison, Wisconsin, as part of a $200 million strategic investment by Fujifilm. - The facility is expected to quadruple the company's manufacturing capacity for iPSC-based research products and expand capabilities for next-generation cell therapy development. - The expansion addresses growing demand from pharmaceutical companies for new approach methods (NAMs) in drug discovery as regulatory guidance shifts away from animal testing. - The facility integrates state-of-the-art capabilities including cell culture manufacturing laboratories, process development laboratories, and a center of excellence for gene editing.
- A Phase 2 randomized controlled trial published in Nature Medicine demonstrates favipiravir achieved a hazard ratio of 0.50 for mortality compared to ribavirin in Lassa fever patients, representing a 50% reduction in death risk. - The SAFARI trial marks the first regulatory-compliant randomized controlled clinical trial evaluating a new Lassa fever treatment in 40 years, conducted in Nigeria's highest-transmission regions with 41 participants. - All study participants survived and were successfully discharged, with favipiravir showing better tolerability than ribavirin, particularly reduced anemia risk which required blood transfusion in one ribavirin patient. - The results challenge ribavirin's four-decade dominance as standard care, as systematic reviews have questioned the evidence base supporting its use since the original 1986 McCormick study.
- The global liposome development and manufacturing services market is projected to grow to $2.34 billion by 2035 at a 9.7% CAGR, driven by increasing demand for drug delivery solutions. - Over 800 clinical trials related to liposomes have been registered to date, with 38% conducted across European clinical sites, highlighting significant therapeutic interest. - Approximately 40% of marketed drugs and 90% of drug candidates under development face solubility and bioavailability issues, creating substantial demand for liposome-based delivery systems. - More than 70 service providers currently offer liposome development and manufacturing services, with therapeutic formulations dominating the market over nutraceutical applications.
- The FDA has granted orphan drug designation to FF-10832, FUJIFILM's investigational liposomal formulation of gemcitabine, for treating biliary tract cancer. - Phase 1 study results presented at ASCO 2025 demonstrated that FF-10832 is well tolerated and shows anti-tumor activity in patients with advanced biliary tract cancer. - The novel liposomal formulation is designed to enhance anti-tumor activity by prolonging plasma half-life and improving targeted delivery to tumors. - Biliary tract cancer affects approximately 16,000 new patients annually in the U.S., with most presenting with unresectable or metastatic disease and poor survival rates.
